Pharmaceuticals and Medical Devices Agency

This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

# Summary of investigation results Rebamipide

March 24, 2015

## Non-proprietary name

Rebamipide (ophthalmic solution)

## Brand name (Marketing authorization holder)

Mucosta Ophthalmic Suspension UD 2% (Otsuka Pharmaceutical Co., Ltd.)

## Indications

Dry eyes

### **Summary of revision**

The Clinically significant adverse reactions section should include 'lacrimal duct obstruction and dacryocystitis.'

## Background of the revision and investigation results

Cases of adverse events suggestive of lacrimal duct obstruction or dacryocystitis have been reported in patients treated with rebamipide ophthalmic solution in Japan. Following an investigation based on the opinions of expert advisors and available evidence, the MHLW/PMDA concluded that revision of the package insert was necessary.

#### The number of reported adverse reactions and fatal cases in the last 3 fiscal years in Japan

A total of 8 cases of adverse events suggestive of lacrimal duct obstruction or dacryocystitis have been reported (including 5 cases in which causality could not be ruled out). No fatalities have been reported.

Pharmaceuticals and Medical Devices Agency Office of Safety I 3·3·2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>